Novartis: announces results of Kisqali trial

(CercleFinance.com) - Novartis announced results from the Phase II RIGHT Choice trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) versus combination chemotherapy (CT) in first-line patients with aggressive pre- and peri-menopausal metastatic breast cancer (MBC) (HR+/HER2-).


Kisqali demonstrated a progression-free survival (PFS) benefit of nearly one year in the study, supporting the superiority of Kisqali plus ET for this difficult-to-treat patient population.

Data from this open-label, multinational study will be presented as a late-breaking oral presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) and included in the SABCS press program.


Copyright (c) 2022 CercleFinance.com. All rights reserved.